Browse the full record of transactions filed by ADVICENNE SA, Chief Executive Officer. Director active across 1 companies, notably ADVICENNE. Aggregated, 1 disclosures have been logged. Total volume traded: €231k. The latest transaction was filed on 18 September 2025 — Acquisition. Regulator: AMF. All data is openly available.
1 of 1 declaration
Didier Laurens is currently the Chief Executive Officer and Chief Financial Officer of Advicenne SA, a French listed pharmaceutical company focused on rare kidney diseases. He joined Advicenne in May 2021 as Chief Executive Officer and later also took on the finance role, making him one of the company’s most important executives for both strategic execution and financial oversight. His background combines corporate finance expertise with hands-on leadership in healthcare and life sciences businesses, particularly in regulated and growth-oriented environments. Prior to joining Advicenne, Didier Laurens held several senior finance positions in the medtech, biotech, and healthcare sectors. He served as Chief Financial Officer of Ecential Robotics, a private medical technology company commercializing robotic solutions for spine surgery. He also worked as Chief Financial Officer of Pixium Vision, a company listed on Euronext Paris, and as interim Chief Financial Officer of Korian, after previously being in charge of financing, treasury, and investor relations. These roles gave him broad experience in capital markets, financial planning, investor communication, balance-sheet management, and operational control. At Advicenne, Laurens plays a central role during a period of transformation. The company has reinforced its governance by separating the roles of Chairman of the Board and Chief Executive Officer, in line with a governance framework designed to clearly distinguish executive management from board supervision. Within that structure, he is responsible for driving execution, supporting operational priorities, and overseeing the company’s financial discipline. His leadership has coincided with a phase in which Advicenne has been advancing the development and commercialization of therapies for rare renal disorders, an area that requires strong regulatory expertise, capital allocation discipline, and long-term strategic vision. His combined executive and financial profile makes him a pivotal figure in the company’s development and governance.